Acetyl-CoA carboxylase 2 inhibition reduces skeletal muscle bioactive lipid content and attenuates progression of type 2 diabetes in Zucker diabetic fatty rats

Eur J Pharmacol. 2021 Nov 5:910:174451. doi: 10.1016/j.ejphar.2021.174451. Epub 2021 Aug 27.

Abstract

Intramyocellular lipid (IMCL) accumulation in skeletal muscle is closely associated with development of insulin resistance. In particular, diacylglycerol and ceramide are currently considered as causal bioactive lipids for impaired insulin action. Recently, inhibition of acetyl-CoA carboxylase 2 (ACC2), which negatively modulates mitochondrial fatty acid oxidation, has been shown to reduce total IMCL content and improve whole-body insulin resistance. This study aimed to investigate whether ACC2 inhibition-induced compositional changes in bioactive lipids, especially diacylglycerol and ceramide, within skeletal muscle contribute to the improved insulin resistance. In skeletal muscle of normal rats, treatment of the ACC2 inhibitor compound 2e significantly decreased both diacylglycerol and ceramide levels while having no significant impact on other lipid metabolite levels. In skeletal muscle of Zucker diabetic fatty (ZDF) rats, which exhibited greater lipid accumulation than that of normal rats, compound 2e significantly decreased diacylglycerol and ceramide levels corresponding to reduced long chain acyl-CoA pools. Additionally, in the lipid metabolomics study, ZDF rats treated with compound 2e also showed improved diabetes-related metabolic disturbance, as reflected by delayed hyperinsulinemia as well as upregulated gene expression associated with diabetic conditions in skeletal muscle. These metabolic improvements were strongly correlated with the bioactive lipid reductions. Furthermore, long-term treatment of compound 2e markedly improved whole-body insulin resistance, attenuated hyperglycemia and delayed insulin secretion defect even at severe diabetic conditions. These findings suggest that ACC2 inhibition decreases diacylglycerol and ceramide accumulation within skeletal muscle by enhancing acyl-CoA breakdown, leading to attenuation of lipid-induced insulin resistance and subsequent diabetes progression.

Keywords: Acetyl-CoA carboxylase 2; Diabetes; Insulin resistance; Lipid accumulation; Skeletal muscle.

MeSH terms

  • Acetyl Coenzyme A / drug effects
  • Acetyl Coenzyme A / metabolism
  • Acetyl-CoA Carboxylase / antagonists & inhibitors*
  • Alkenes / pharmacokinetics
  • Alkenes / pharmacology*
  • Alkenes / therapeutic use
  • Animals
  • Ceramides / metabolism
  • Correlation of Data
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism*
  • Diglycerides / metabolism
  • Enzyme Inhibitors / pharmacokinetics
  • Enzyme Inhibitors / pharmacology*
  • Enzyme Inhibitors / therapeutic use
  • Insulin Resistance
  • Lipid Metabolism / drug effects*
  • Lipids / analysis
  • Male
  • Muscle, Skeletal / metabolism*
  • Oxidation-Reduction / drug effects
  • Rats
  • Rats, Sprague-Dawley
  • Rats, Zucker
  • Triglycerides / metabolism

Substances

  • ACC2 inhibitor compound 2e
  • Alkenes
  • Ceramides
  • Diglycerides
  • Enzyme Inhibitors
  • Lipids
  • Triglycerides
  • Acetyl Coenzyme A
  • Acetyl-CoA Carboxylase